<?xml version="1.0" encoding="UTF-8"?>
<p id="Par50">Among several non-specific anti-viral approaches to reduce asthma include strategies aiming at enhancing the patientâ€™s resistance to multiple respiratory viruses through the administration of immunostimulatory preparations [
 <xref ref-type="bibr" rid="CR66">66</xref>, 
 <xref ref-type="bibr" rid="CR89">89</xref>]. Pidotimod is a synthetic thymic dipeptide that appears to share several mechanistic similarities with bacterial immunomodulators, and it is thought to stimulate toll-like receptor 2 (TLR2) and TLR4, which are expressed on DCs, this displaying anti-infective effects. To date, there is only one prospective multicenter trial, showing that pidotimod reduced the number of respiratory infections in a mixed group of children over half of whom had atopic conditions, including asthma [
 <xref ref-type="bibr" rid="CR90">90</xref>].
</p>
